Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Eide

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Blood|October 9, 2014
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoproteinAnupriya Agarwal, Ryan J Mackenzie, Arnaud Besson, et al.
Oncotarget|February 11, 2017
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitorsPaavo O Pietarinen, Christopher A Eide, Pilar Ayuda-Durán, et al.
Oncogene|March 13, 2021
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa BAlfonso E Bencomo-Alvarez, Andres J Rubio, Idaly M Olivas, et al.
Leukemia|June 19, 2019
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemiaSusan Branford, Dennis Dong Hwan Kim, Jane F Apperley, et al.
Cancer Research|April 12, 2013
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosisThomas O'Hare, Christopher A Eide, Anupriya Agarwal, et al.
Blood Cancer Discovery|September 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapyChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Blood|February 7, 2008
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemiaMarc M Loriaux, Ross L Levine, Jeffrey W Tyner, et al.
The New England Journal of Medicine|May 10, 2013
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLJulia E Maxson, Jason Gotlib, Daniel A Pollyea, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 9, 2017
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignanciesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2024
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid LeukemiaRucha V Modak, Katia G de Oliveira Rebola, John McClatchy, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Blood|October 9, 2014
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoproteinAnupriya Agarwal, Ryan J Mackenzie, Arnaud Besson, et al.
Oncotarget|February 11, 2017
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitorsPaavo O Pietarinen, Christopher A Eide, Pilar Ayuda-Durán, et al.
Oncogene|March 13, 2021
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa BAlfonso E Bencomo-Alvarez, Andres J Rubio, Idaly M Olivas, et al.
Leukemia|June 19, 2019
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemiaSusan Branford, Dennis Dong Hwan Kim, Jane F Apperley, et al.
Cancer Research|April 12, 2013
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosisThomas O'Hare, Christopher A Eide, Anupriya Agarwal, et al.
Blood Cancer Discovery|September 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapyChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Blood|February 7, 2008
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemiaMarc M Loriaux, Ross L Levine, Jeffrey W Tyner, et al.
The New England Journal of Medicine|May 10, 2013
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLJulia E Maxson, Jason Gotlib, Daniel A Pollyea, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 9, 2017
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignanciesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2024
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid LeukemiaRucha V Modak, Katia G de Oliveira Rebola, John McClatchy, et al.
Pageof 12